Data for ST001740   

(Analysis AN002833): Average values per metabolite and experimental factor (Units:Relative intensity)

Metabolite structureAll dataF1F2F3F4F5F6F7F8F9F10F11F12F13F14F15F16F17F18F19F20F21F22F23F24F25F26F27F28F29F30F31F32F33F34F35F36F37F38F39F40F41F42F43F44F45
Phosphatidylinositol(16:0/18:1)
0.88 1.04 0.77 0.58 1.33 1.66 3.51 1.35 1.10 0.68 1.02 0.96 0.70 0.70 2.82 3.50 1.81 1.25 1.13 1.69 2.87 0.89 0.97 2.50 4.26 10.72 1.78 1.87 3.61 3.73 0.86 1.28 4.64 3.33 7.55 3.61 1.00 0.88 1.64 1.50 1.08 1.65 4.31 7.85 0.95
Phosphatidylinositol(16:0/20:3 n-6)
0.81 0.95 0.86 0.79 0.71 0.72 0.79 0.72 0.68 0.77 0.67 0.66 0.67 0.49 0.90 1.16 0.91 0.72 0.56 0.78 1.55 0.53 0.65 0.84 1.57 2.49 0.78 0.57 1.43 1.32 0.36 0.45 0.99 1.12 2.52 0.74 0.58 0.67 0.93 0.67 0.73 0.96 1.50 2.08 0.70
Phosphatidylinositol(16:0/20:4)
5.76 5.55 5.47 6.17 5.56 5.08 6.26 6.17 5.84 4.75 5.43 5.95 5.67 5.36 4.45 5.91 6.08 5.77 3.46 5.45 4.41 3.99 5.92 5.37 4.46 4.36 5.59 3.92 6.10 4.52 3.19 6.22 5.10 4.01 5.08 5.35 5.21 5.89 5.61 4.60 5.88 5.55 4.76 5.91 5.96
Phosphatidylinositol(16:1/18:1)
1.05 1.00 1.04 0.91 1.65 1.99 3.58 1.21 1.34 0.92 1.17 1.00 1.07 1.09 2.66 3.57 1.15 1.27 1.03 1.90 2.81 1.37 0.91 2.50 3.50 3.29 2.23 1.11 2.51 3.27 1.54 1.39 4.95 1.89 1.95 4.32 1.12 1.04 2.16 1.25 1.00 2.08 3.22 2.84 1.16
Phosphatidylinositol(18:0/20:3 n-6)
4.50 5.50 5.04 4.63 5.19 5.62 4.55 5.04 5.30 4.71 5.37 5.16 5.33 5.60 6.07 5.02 6.30 5.05 5.69 5.54 9.34 6.26 5.06 5.45 10.78 14.43 5.85 7.59 7.24 10.12 5.57 4.33 4.95 13.78 15.18 5.89 4.80 4.92 6.77 5.86 5.52 6.01 8.27 11.78 5.58
Phosphatidylinositol(18:0/20:4)
57.53 55.84 57.46 57.52 53.25 51.10 40.16 54.44 54.94 60.13 57.82 56.66 58.93 58.61 44.84 37.72 56.22 56.17 67.53 51.69 40.85 65.04 62.45 42.13 36.46 21.69 48.90 64.23 47.76 38.18 66.96 64.36 32.94 42.18 31.59 40.35 60.03 58.87 48.71 60.65 62.73 48.08 35.41 38.22 56.04
Phosphatidylinositol(18:0/22:5)
2.02 2.22 2.22 1.97 1.94 2.41 2.05 2.06 2.15 2.08 2.08 2.06 2.03 1.97 3.19 2.33 2.63 1.80 1.88 2.25 3.46 2.05 2.11 1.84 3.91 9.84 1.84 2.27 2.56 3.23 1.80 1.99 1.54 4.87 7.42 1.61 1.93 2.14 2.20 2.56 2.02 2.79 3.07 5.59 2.18
Phosphatidylinositol(18:0/22:6)
1.17 1.55 1.11 1.01 1.20 1.50 1.47 1.37 1.22 1.30 1.30 1.51 1.14 1.30 2.16 1.59 1.77 1.12 0.94 1.30 2.77 1.17 1.19 1.47 2.21 8.12 1.24 1.01 1.49 2.12 0.63 0.85 1.02 2.29 5.81 1.05 0.89 0.90 1.58 1.53 1.18 1.50 1.88 3.46 1.27
Phosphatidylinositol(18:1/18:1)
5.11 5.64 4.63 4.66 7.23 8.92 13.60 5.91 6.39 4.98 5.31 5.43 4.13 4.91 14.21 14.85 6.06 6.59 4.00 8.11 10.20 3.93 4.31 13.37 14.73 11.30 9.72 5.43 10.16 10.91 3.88 4.15 22.25 10.12 8.57 17.41 4.56 5.37 7.80 4.99 3.94 9.67 16.79 9.61 5.70
Phosphatidylinositol(18:1/20:3 n-6)
2.63 2.58 2.24 2.06 3.01 2.39 3.24 2.52 2.60 2.49 2.12 2.40 2.04 2.40 2.69 3.15 2.12 2.53 1.98 2.80 3.85 1.52 1.44 3.34 3.27 2.25 2.83 1.88 2.38 4.67 1.73 1.32 3.09 3.02 2.23 2.51 2.07 2.09 3.08 1.51 1.57 2.94 4.16 1.54 2.52
Phosphatidylinositol(18:1/20:4)
16.17 15.51 16.93 17.31 16.11 15.77 17.00 16.64 15.84 14.80 14.95 15.53 15.95 15.29 12.73 17.53 12.11 15.13 10.24 15.96 14.61 11.29 12.87 17.66 10.43 4.59 16.41 7.71 11.42 14.38 11.26 11.52 13.78 8.02 6.29 13.18 15.30 15.02 16.50 12.18 12.42 15.73 12.47 4.99 15.54
Phosphatidylinositol(18:1/20:5)
1.89 2.08 1.81 2.06 2.16 1.79 2.47 2.15 1.82 1.84 1.82 2.00 1.96 1.75 2.00 2.40 1.71 1.94 0.72 1.45 1.74 1.13 1.23 2.07 1.33 0.56 1.83 0.83 1.27 1.69 1.45 1.18 1.83 0.95 0.35 1.68 1.77 1.77 2.08 1.41 1.30 2.04 1.90 0.60 1.71

Factors:

F1hours:0.17 | treatment:CHX | concentration:20 µg/ml
F2hours:0.17 | treatment:ETO | concentration:10 µM
F3hours:0.17 | treatment:MC | concentration:10 µM
F4hours:0.17 | treatment:Serum | concentration:-
F5hours:0.17 | treatment:STS | concentration:0.3 µM
F6hours:0.17 | treatment:TNFα | concentration:10 ng/ml
F7hours:0.17 | treatment:TPG | concentration:2 µM
F8hours:0.17 | treatment:VAL | concentration:10 µM
F9hours:0.17 | treatment:vehicle (DMSO) | concentration:-
F10hours:1 | treatment:CHX | concentration:20 µg/ml
F11hours:1 | treatment:ETO | concentration:10 µM
F12hours:1 | treatment:MC | concentration:10 µM
F13hours:1 | treatment:Serum | concentration:-
F14hours:1 | treatment:STS | concentration:0.3 µM
F15hours:1 | treatment:TNFα | concentration:10 ng/ml
F16hours:1 | treatment:TPG | concentration:2 µM
F17hours:1 | treatment:VAL | concentration:10 µM
F18hours:1 | treatment:vehicle (DMSO) | concentration:-
F19hours:24 | treatment:CHX | concentration:20 µg/ml
F20hours:24 | treatment:ETO | concentration:10 µM
F21hours:24 | treatment:MC | concentration:10 µM
F22hours:24 | treatment:Serum | concentration:-
F23hours:24 | treatment:STS | concentration:0.3 µM
F24hours:24 | treatment:TNFα | concentration:10 ng/ml
F25hours:24 | treatment:TPG | concentration:2 µM
F26hours:24 | treatment:VAL | concentration:10 µM
F27hours:24 | treatment:vehicle (DMSO) | concentration:-
F28hours:48 | treatment:CHX | concentration:20 µg/ml
F29hours:48 | treatment:ETO | concentration:10 µM
F30hours:48 | treatment:MC | concentration:10 µM
F31hours:48 | treatment:Serum | concentration:-
F32hours:48 | treatment:STS | concentration:0.3 µM
F33hours:48 | treatment:TNFα | concentration:10 ng/ml
F34hours:48 | treatment:TPG | concentration:2 µM
F35hours:48 | treatment:VAL | concentration:10 µM
F36hours:48 | treatment:vehicle (DMSO) | concentration:-
F37hours:6 | treatment:CHX | concentration:20 µg/ml
F38hours:6 | treatment:ETO | concentration:10 µM
F39hours:6 | treatment:MC | concentration:10 µM
F40hours:6 | treatment:Serum | concentration:-
F41hours:6 | treatment:STS | concentration:0.3 µM
F42hours:6 | treatment:TNFα | concentration:10 ng/ml
F43hours:6 | treatment:TPG | concentration:2 µM
F44hours:6 | treatment:VAL | concentration:10 µM
F45hours:6 | treatment:vehicle (DMSO) | concentration:-
  logo